Drug Discovery– tag –
-
Oncology Drug Approval News Flash: Pembrolizumab plus paclitaxel with or without bevacizumab approved for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
FDA approval summary On February 10, 2026, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) and pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with paclitaxel, with... -
From Beginner to Expert: AI in Drug Discovery – A Definitive Guide from Lab to Market (Extra Chapter, Snapshot as of November 22, 2025) focuses only on the latest AI-driven case studies and summarizes how far AI has actually progressed in real drug discovery and development.
1. Where Does AI in Drug Discovery Stand in 2025? Between 2024 and 2025, AI in drug discovery has quietly moved from the “proof-of-concept” phase into a stage where AI-designed molecules are showing signals in human trials. Between 2024 ... -
From Beginner to Expert: AI in Drug Discovery – A Definitive Guide from Lab to Market (Part 7: “Putting It All Together”) summarizes a cross-modality roadmap for AI in drug discovery and development, clarifies what AI can and cannot realistically do, and outlines strategic considerations from lab bench to market access.
1. Recap: A Cross-Modality “AI in Drug Discovery” Map In Parts 1–6, we walked through: What you will learn 1. Recap: A Cross-Modality “AI in Drug Discovery” Map2. Phase-by-Phase Roadmap: From Discovery to Post-Marketing3. Strengths and W... -
From Beginner to Expert: AI in Drug Discovery – A Definitive Guide from Lab to Market (Part 6: “Cell & Gene Therapy × AI”) maps how AI is used from CAR-T/TCR and vector design to manufacturing and quality control, and clarifies both its potential and its current limitations in these complex modalities.
1. Why “Cell & Gene Therapy × AI” Is Both Difficult and Important In Part 6, we focus on cell therapies (e.g., CAR-T, TCR-T) and gene therapies (e.g., AAV or lentiviral vectors). Compared with small molecules, antibodies, or RNA ther... -
Aging and Cancer Extra Edition – Part 2 The Global Frontline of Longevity Biotech: What Are Unity, BioAge, Cambrian, and Altos Trying to Achieve?
Introduction: Aging Is Becoming an Industry In Extra Edition Part 1, we introduced the concept of “anti-aging drugs” by looking at major mechanisms such as mTOR, metformin, senolytics, NAD⁺, and cellular reprogramming. In Extra Edition P... -
How Far Can We Trust Genome AI? — Reading AlphaGenome (Nature) with an Implementation Mindset (Expert Edition)
In the beginner edition, we focused on why the “other 98%” of DNA (non-coding regions) is hard to interpret and why genome AI should be framed as hypo In the beginner edition, we focused on why the “other 98%” of DNA (non-coding regions)... -
Aging and Cancer Extra Edition – Part 1 What Are “Anti-Aging Drugs”? An Introductory Guide from Metformin and mTOR to Senolytics and “Rejuvenation”
Introduction: Why Are “Anti-Aging Drugs” a Hot Topic Now? When you hear “anti-aging drugs” or “rejuvenation pills,” you might imagine dubious supplements or flashy beauty ads. When you hear “anti-aging drugs” or “rejuvenation pills,” you... -
What Does the “Other 98%” of DNA Do? — A Beginner-Friendly Guide to Genome AI (What DeepMind’s AlphaGenome Suggests)
When people hear “genome analysis,” they often imagine a simple story: read DNA, find a mutation, and explain a disease. In reality, the deeper we read, the more often we hit a frustrating wall: we can detect many variants, but we can’t ... -
From Beginner to Expert: AI in Drug Discovery – A Definitive Guide from Lab to Market (Part 5: “Nucleic Acid & RNA Therapeutics × AI”) summarizes how AI is used for sequence design, target selection, delivery optimization, and safety assessment for RNA and nucleic-acid medicines.
1. Why “Nucleic Acid & RNA Therapeutics × AI” Matters mRNA vaccines, siRNA, antisense oligonucleotides (ASOs), saRNA, and CRISPR guide RNAs have rapidly moved from concept to clinical reality. mRNA vaccines, siRNA, antisense oligonuc... -
The more important question than “present or absent”: how microbial elements may tune immunity in brain tumors
Brain tumors sit at the crossroads of immunology and microbiology, but they are also a uniquely challenging environment to study. Brain tumors sit at the crossroads of immunology and microbiology, but they are also a uniquely challenging... -
From Beginner to Expert: AI in Drug Discovery – A Definitive Guide from Lab to Market (Part 4: “Antibodies & Biologics × AI”) explores how AI is applied to sequence design, affinity maturation, and developability prediction, and how this differs from small-molecule use cases.
1. Why “Antibodies & Biologics × AI” Is Different from Small Molecules In Part 3, we focused on small-molecule projects. In Part 3, we focused on small-molecule projects. In Part 4, we turn to antibodies and biologics (including anti... -
Oncology Drug Approval News Flash: Daratumumab and hyaluronidase-fihj plus bortezomib, lenalidomide, and dexamethasone approved for newly diagnosed multiple myeloma in transplant-ineligible adults
FDA approval summary On January 27, 2026, the U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (V... -
From Beginner to Expert: AI in Drug Discovery – A Definitive Guide from Lab to Market (Part 3: “Small Molecules × AI”) walks through how AI is actually used from hit finding to lead optimization, highlighting concrete use cases, benefits, and limitations.
1. Why Small Molecules Became the Primary Testbed for AI When you scan AI-in-drug-discovery papers and case studies, the first thing you notice is how many of them focus on small molecules. When you scan AI-in-drug-discovery papers and c... -
The Word “Vaccine” Breaks the Conversation: How Far Have Cancer Vaccines Actually Come?
The moment the word “vaccine” appears, conversations tend to heat up—and then collapse. The moment the word “vaccine” appears, conversations tend to heat up—and then collapse. This happens in infectious disease, and it also happens in ca... -
From Beginner to Expert: AI in Drug Discovery – A Definitive Guide from Lab to Market (Part 2: “Data and Algorithms Behind AI-Driven R&D”) explains which data types AI relies on, what sources those data come from, and how representative model families are used in practice.
1. Data and Models: The Core of AI in Drug Discovery In Part 1, we mapped where AI can plug into the drug discovery and development value chain and what it can – and cannot – do. In Part 1, we mapped where AI can plug into the drug disco... -
From Beginner to Expert: AI in Drug Discovery – A Definitive Guide from Lab to Market (Part 1: “What Is AI in Drug Discovery?”) maps the entire R&D-to-market value chain and clarifies what AI can – and still cannot – do.
1. Why AI in Drug Discovery Is in the Spotlight Now “AI in drug discovery” has become a buzzword in recent years, but it is not a magic technology that appeared overnight. “AI in drug discovery” has become a buzzword in recent years, but... -
JPM2026 Key Topics Series Part 3: How to Read CEO Remarks — Companies That Speak With Numbers vs. Companies That Signal Posture
At JPM some CEOs speak in numbers, others in posture. The real signal lies in what is left unsaid—decoded through five years of pattern recognition. Here is the framework for separating noise from intent. At JPM2026, CEO remarks drew out... -
JPM2026 Key Topics Series Part 2: Why Mega-M&A Didn’t Show Up — Yet Capital and Deals Still Moved
One of the defining “feelings” at JPM2026 was that the conference was crowded and energetic—yet true mega-M&A headlines were scarce. One of the defining “feelings” at JPM2026 was that the conference was crowded and energetic—yet true... -
JPM2026 Key Topics Series Part 1: Obesity & Metabolic (GLP-1) — The Battle Has Moved to Execution
At JPM2026, obesity and metabolic disease (GLP-1) remained the gravitational center of the conference. At JPM2026, obesity and metabolic disease (GLP-1) remained the gravitational center of the conference. Yet the most decisive conversat... -
Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention (Series Hub)
This series places women’s cancer risk on a single life-course map—from puberty and reproductive years to pregnancy/childbirth, the menopause transition, and postmenopause. This series places women’s cancer risk on a single life-course m...
